PT - JOURNAL ARTICLE AU - Alexis Régent AU - Serge Redeker AU - Alban Deroux AU - Pierre Kieffer AU - Kim Heang Ly AU - Maxime Dougados AU - Eric Liozon AU - Claire Larroche AU - Loïc Guillevin AU - Laurence Bouillet AU - Olivier Espitia AU - Nathalie Costedoat-Chalumeau AU - Martin Soubrier AU - Benoît Brihaye AU - François Lifermann AU - Guillaume Lefevre AU - Xavier Puéchal AU - Luc Mouthon AU - Eric Toussirot AU - for the French Vasculitis Group, the Groupe Francais pour l’Etude de l’Artérite à Cellules Géantes, and the Club Rhumatismes et Inflammation TI - Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients AID - 10.3899/jrheum.151252 DP - 2016 Aug 01 TA - The Journal of Rheumatology PG - 1547--1552 VI - 43 IP - 8 4099 - http://www.jrheum.org/content/43/8/1547.short 4100 - http://www.jrheum.org/content/43/8/1547.full SO - J Rheumatol2016 Aug 01; 43 AB - Objective. To report the efficacy and safety of tocilizumab (TCZ) for giant cell arteritis (GCA).Methods. A retrospective multicenter study that included 34 patients receiving TCZ for GCA.Results. TCZ was effective in all but 6 patients, who still had mild symptoms. Mean glucocorticoid dose was tapered. One patient died and 3 patients had to stop TCZ therapy because of severe adverse events. Twenty-three patients stopped treatment; 8 of these experienced relapses after a mean of 3.5 ± 1.3 months.Conclusion. TCZ is effective in GCA. However, side effects occur. Whether this treatment has only a suspensive effect remains to be determined.